Pulmatrix (NASDAQ:PULM) Stock Price Passes Below 50 Day Moving Average – Time to Sell?

Shares of Pulmatrix, Inc. (NASDAQ:PULM) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.39 and traded as low as $1.20. Pulmatrix shares last traded at $1.23, with a volume of 52,945 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Pulmatrix Price Performance

The stock has a market capitalization of $4.49 million, a P/E ratio of -0.87 and a beta of 1.67. The firm has a 50-day simple moving average of $2.39 and a 200 day simple moving average of $3.51.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.25) earnings per share for the quarter.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP purchased a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix as of its most recent filing with the Securities and Exchange Commission. 11.84% of the stock is owned by institutional investors and hedge funds.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).